突破抗癌药物研发瓶颈：合成生物学的高效利用。

Breaking the Bottleneck in Anticancer Drug Development: Efficient Utilization of Synthetic Biology.

机构信息

Department of Laboratory Medicine, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu 610072, China.

Sichuan Provincial Key Laboratory for Human Disease Gene Study, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu 610072, China.

出版信息

Molecules. 2022 Nov 2;27(21):7480. doi: 10.3390/molecules27217480.

DOI:10.3390/molecules27217480

PMID:36364307

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9656990/

Abstract

Natural products have multifarious bioactivities against bacteria, fungi, viruses, cancers and other diseases due to their diverse structures. Nearly 65% of anticancer drugs are natural products or their derivatives. Thus, natural products play significant roles in clinical cancer therapy. With the development of biosynthetic technologies, an increasing number of natural products have been discovered and developed as candidates for clinical cancer therapy. Here, we aim to summarize the anticancer natural products approved from 1950 to 2021 and discuss their molecular mechanisms. We also describe the available synthetic biology tools and highlight their applications in the development of natural products.

摘要

天然产物由于其多样的结构，对细菌、真菌、病毒、癌症和其他疾病具有多种生物活性。近 65%的抗癌药物是天然产物或其衍生物。因此，天然产物在癌症的临床治疗中发挥着重要作用。随着生物合成技术的发展，越来越多的天然产物被发现并开发为临床癌症治疗的候选药物。在这里，我们旨在总结 1950 年至 2021 年批准的抗癌天然产物，并讨论它们的分子机制。我们还描述了现有的合成生物学工具，并强调了它们在天然产物开发中的应用。